Why these two treatments are often confused

Patients researching cartilage care at Lincolnshire Hip frequently encounter two brand names — ChondroFiller® and Liquid Cartilage™ — and assume they are rival products competing for the same clinical role. They are not. Both were developed by Professor Paul Lee, both are offered at the Lincolnshire Hip clinic, and crucially, both are built on exactly the same implant: ChondroFiller® liquid, a CE-marked Class III medical device composed of murine-derived Type I collagen that gels in place after injection to form a biological scaffold.

The confusion is understandable. Different names, different price points, and different descriptions of what happens during treatment can make these look like distinct materials from different sources. In practice, the material at the centre of each pathway is identical. What differs is the clinical route by which it reaches the hip joint, and the patient profile that each route suits. One approach delivers the scaffold in an outpatient clinic setting; the other incorporates it into a surgical procedure alongside the patient's own cells, for cases where a straightforward injection is not enough.

Framing this as a 'better versus worse' choice misses the point. The right question is not which product is superior — it is which pathway matches what your hip joint actually needs.

How ChondroFiller® injection works in the hip joint

An outpatient appointment is all the procedure requires. Under ultrasound guidance, the ChondroFiller® collagen solution is injected directly into the hip joint — no theatre admission, no general anaesthetic, and no overnight stay. Most patients go home the same day.

Once inside the joint, the solution self-gels within minutes, forming a stable biological scaffold that coats the load-bearing cartilage surface. Think of it as an additive cushion laid over the worn areas from the top down, rather than a surgical excavation and rebuilding from below. This is what sets the injection apart from hyaluronic acid: HA is a lubricant that the joint clears within weeks and does not interact with the tissue; ChondroFiller® is a native collagen structure that remains in place and integrates with the hip joint over time.

The repair mechanism is called acellular matrix-induced chondrogenesis. In plain terms, the scaffold itself contains no cells — instead it acts as a chemotactic signal, drawing the patient's own progenitor cells in from the surrounding synovium and subchondral bone. Those cells populate the scaffold, mature into chondrocytes, and gradually produce cartilage-like tissue as the collagen is slowly resorbed. The hip joint, in effect, does the regenerative work; the scaffold supports the process.

Because the protective effect is provided by the physical scaffold rather than by the body regenerating large volumes of new tissue, there is no upper age limit and no defect-size exclusion. This makes the injection a realistic option for patients with diffuse hip cartilage wear or cases approaching bone-on-bone contact — groups for whom a cell-dependent surgical approach may be less appropriate.

How Liquid Cartilage™ differs in approach and indication

Where ChondroFiller® injection works from the surface down, Liquid Cartilage™ targets the defect from its base. The underlying implant is the same collagen scaffold — but in this pathway it arrives alongside the patient's own signalling cells, harvested from bone marrow, adipose tissue, or platelet-rich fibrin and prepared at the point of care. The scaffold and cells are co-delivered in a single clinic visit, without theatre admission or general anaesthetic.

That cellular partnership changes what becomes possible. Rather than relying on the scaffold to attract progenitor cells from the surrounding joint over time, Liquid Cartilage™ places those cells directly at the defect site, where they may promote endogenous repair from the base of the lesion upward. This is the structural distinction: the injection pathway cushions and recruits; the cellular pathway targets regeneration of a focal area of damage from the ground up.

The clinical trade-off is that this approach demands more of the patient's own biology. Liquid Cartilage™ suits a focal, contained hip cartilage lesion — one where surrounding cartilage is reasonably preserved and the damaged zone has defined borders — rather than the diffuse, whole-joint wear that favours the injection. Eligibility also depends on the patient's assessed regenerative capacity, which Professor Lee evaluates at consultation using MRI findings alongside clinical history. It is not a pathway available to all ages or all defect patterns.

Professor Lee has continued to refine the concept through NanoACi™, a needle-delivered, one-stage autologous protocol that combines the collagen scaffold with cartilage micrografts and autologous platelet-rich fibrin in one sitting. Combined-protocol outcomes are still in prospective collection. As the approach continues to develop, the Lincolnshire Hip team can advise at consultation which variant is currently offered.

How the right pathway is chosen for your hip

Two variables sit at the heart of the decision: what the MRI shows, and what the hip joint actually needs.

When imaging reveals diffuse cartilage thinning across the joint surface — or where wear has progressed to the point of bone-on-bone contact — the ChondroFiller® injection pathway is generally the more appropriate option. Because the scaffold works as an additive cushion rather than depending on the body regenerating a large volume of new tissue, it remains viable without an upper age limit or defect-size ceiling. Patients for whom a more involved procedure carries greater risk often fall into this group too.

Liquid Cartilage™ suits a different hip picture: a focal, contained area of cartilage damage with reasonably preserved surrounding tissue and clearly defined lesion borders. Younger patients with adequate regenerative capacity and this specific MRI pattern are the candidates most likely to benefit from the scaffold-plus-cells approach. Where surrounding cartilage is already compromised or the damage is widespread, the cellular pathway offers less of an advantage.

Neither route is selected on cost or patient preference alone. At consultation, Professor Lee assesses MRI findings alongside clinical history to map the hip's actual state. ChondroFiller® injection and Liquid Cartilage™ are both considered in the context of the full treatment menu — which at Lincolnshire Hip also includes PRP and Arthrosamid — so the recommendation reflects what the hip needs rather than what is simply available.

What the evidence shows — and where the gaps are

Published outcome figures for ChondroFiller® come primarily from knee cohorts. The Jerosch et al. post-market clinical follow-up study recorded a mean IKDC improvement of 32.4 points sustained at three-year follow-up — well above the minimum clinically important difference threshold of 16.7 points. MOCART scores, a validated measure of cartilage tissue quality on MRI, progressed from 65.3 at four weeks to 81.6 at one year in the same cohort, reflecting gradual scaffold maturation rather than an immediate structural change. The complaint rate in available data sits at approximately 0.06%.

For the hip specifically, the knowledge base references a modified Harris Hip Score improvement of approximately 30 points — a meaningful functional gain — though hip-specific published data are not yet reported in the same level of peer-reviewed detail as the knee figures. That gap is worth naming plainly: patients considering ChondroFiller® injection for hip cartilage wear are drawing, in part, on evidence generated in a different joint, and hip-dedicated registry data remain an area of active collection.

The same applies to the Liquid Cartilage™ scaffold-plus-cells protocol. Combined-outcome data from prospective series, including the NanoACi™ cohort, are still being gathered. What exists at component level is encouraging, but longer-term hip-specific results have not been published at the time of writing.

Costs, access, and booking at Lincolnshire Hip

Guide costs at Lincolnshire Hip are £2,995 for the ChondroFiller® injection and £9,800 all-in for the Liquid Cartilage™ pathway — the latter covering consultation, imaging review, the collagen scaffold, MSC co-delivery, anaesthetic, surgical venue, and post-operative review with no add-ons by defect size. Both figures should be confirmed directly with the clinic at the time of booking.

For patients with private health insurance, the Liquid Cartilage™ surgical pathway may be covered under CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500 (arthroscopy). Bupa, Aviva, and WPA have most commonly granted pre-authorisation in reported cases, though approval is never guaranteed and insurers require it to be sought before treatment commences.

Consultations take place locally in Grantham and Sleaford, making access straightforward for patients across Lincolnshire and the surrounding region. Where the Liquid Cartilage™ surgical pathway is indicated, the procedure is performed at Weymouth Street Hospital in London.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.